Immunogenicity and protective efficacy of ApxIA and ApxIIA DNA vaccine against Actinobacillus pleuropneumoniae lethal challenge in murine model

Vaccine

Volumn 27, Issue 34, 2009, Pages 4565-4570

  Chiang, Chung Hao ^a   Huang, Wei Fang ^a   Huang, Li Pu ^a   Lin, Shuen Fuh ^a   Yang, Wen Jen ^a  

^a NATIONAL UNIVERSITY OF KAOHSIUNG   (Taiwan)

Author keywords

Actinobacillus pleuropneumoniae; Apx toxin; DNA vaccine

Indexed keywords

BACTERIAL PROTEIN; DNA VACCINE; EXOTOXIN; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; PROTEIN APXIA; PROTEIN APXIIA; UNCLASSIFIED DRUG;

ACTINOBACILLUS PLEUROPNEUMONIAE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; BACTERIAL GENE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GENE SEQUENCE; HUMORAL IMMUNITY; IMMUNOGENICITY; MOLECULAR CLONING; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PORCINE PLEUROPNEUMONIA; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ACTINOBACILLUS INFECTIONS; ACTINOBACILLUS PLEUROPNEUMONIAE; ANIMALS; ANTIBODIES, BACTERIAL; BACTERIAL PROTEINS; FEMALE; HEMOLYSIN PROTEINS; IMMUNOGLOBULIN G; INJECTIONS, INTRAMUSCULAR; MICE; MICE, INBRED BALB C; SURVIVAL ANALYSIS; SWINE; SWINE DISEASES; VACCINES, DNA;

EID: 67649479221     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.05.058     Document Type: Article

References (39)

1. Taylor D.J. Actinobacillus pleuropneumoniae. In: D'allaire S., Megeling W.L., Taylor D.J., and Straw B.E. (Eds). Diseases of swine. 8th ed. (1999), Iowa State University Press, Ames, IA 343-354
2. Bosse J.T., Janson H., Sheehan B.J., Beddek A.J., Rycroft A.N., Kroll J.S., et al. Actinobacillus pleuropneumoniae: pathobiology and pathogenesis of infection. Microbes Infect 4 2 (2002) 225-235
3. Frey J. Virulence in Actinobacillus pleuropneumoniae and RTX toxins. Trends Microbiol 3 7 (1995) 257-261
4. Dubreuil J.D., Jacques M., Mittal K.R., and Gottschalk M. Actinobacillus pleuropneumoniae surface polysaccharides: their role in diagnosis and immunogenicity. Anim Health Res Rev 1 2 (2000) 73-93
5. Blackall P.J., Klaasen H.L., van den Bosch H., Kuhnert P., and Frey J. Proposal of a new serovar of Actinobacillus pleuropneumoniae: serovar 15. Vet Microbiol 84 1-2 (2002) 47-52
6. Bandara A.B., Lawrence M.L., Veit H.P., and Inzana T.J. Association of Actinobacillus pleuropneumoniae capsular polysaccharide with virulence in pigs. Infect Immun 71 6 (2003) 3320-3328
7. Shakarji L., Mikael L.G., Srikumar R., Kobisch M., Coulton J.W., and Jacques M. Fhua and HgbA, outer membrane proteins of Actinobacillus pleuropneumoniae: their role as virulence determinants. Can J Microbiol 52 4 (2006) 391-396
8. Ramjeet M., Deslandes V., St Michael F., Cox A.D., Kobisch M., Gottschalk M., et al. Truncation of the lipopolysaccharide outer core affects susceptibility to antimicrobial peptides and virulence of Actinobacillus pleuropneumoniae serotype 1. J Biol Chem 280 47 (2005) 39104-39114
9. Boekema B.K., Van Putten J.P., Stockhofe-Zurwieden N., and Smith H.E. Host cell contact-induced transcription of the type IV fimbria gene cluster of Actinobacillus pleuropneumoniae. Infect Immun 72 2 (2004) 691-700
10. Negrete-Abascal E., Reyes M.E., Garcia R.M., Vaca S., Giron J.A., Garcia O., et al. Flagella and motility in Actinobacillus pleuropneumoniae. J Bacteriol 185 2 (2003) 664-668
11. Garcia-Cuellar C., Montanez C., Tenorio V., Reyes-Esparza J., Duran M.J., Negrete E., et al. A 24-kDa cloned zinc metalloprotease from Actinobacillus pleuropneumoniae is common to all serotypes and cleaves actin in vitro. Can J Vet Res 64 2 (2000) 88-95
12. Schaller A., Kuhn R., Kuhnert P., Nicolet J., Anderson T.J., MacInnes J.I., et al. Characterization of apxIVA, a new RTX determinant of Actinobacillus pleuropneumoniae. Microbiology 145 Pt 8 (1999) 2105-2116
13. Boekema B.K., Kamp E.M., Smits M.A., Smith H.E., and Stockhofe-Zurwieden N. Both ApxI and ApxII of Actinobacillus pleuropneumoniae serotype 1 are necessary for full virulence. Vet Microbiol 100 1-2 (2004) 17-23
14. Ramjeet M., Deslandes V., Goure J., and Jacques M. Actinobacillus pleuropneumoniae vaccines: from bacterins to new insights into vaccination strategies. Anim Health Res Rev (2008) 1-21
15. Rioux S., Girard C., Dubreuil J.D., and Jacques M. Evaluation of the protective efficacy of Actinobacillus pleuropneumoniae serotype 1 detoxified lipopolysaccharides or O-polysaccharide-protein conjugate in pigs. Res Vet Sci 65 2 (1998) 165-167
16. Gerlach G.F., Anderson C., Klashinsky S., Rossi-Campos A., Potter A.A., and Willson P.J. Molecular characterization of a protective outer membrane lipoprotein (OmlA) from Actinobacillus pleuropneumoniae serotype 1. Infect Immun 61 2 (1993) 565-572
17. Oldfield N.J., Donovan E.A., Worrall K.E., Wooldridge K.G., Langford P.R., Rycroft A.N., et al. Identification and characterization of novel antigenic vaccine candidates of Actinobacillus pleuropneumoniae. Vaccine 26 11 (2008) 1942-1954
18. Devenish J., Rosendal S., and Bosse J.T. Humoral antibody response and protective immunity in swine following immunization with the 104-kilodalton hemolysin of Actinobacillus pleuropneumoniae. Infect Immun 58 12 (1990) 3829-3832
19. Bagdasarian M.M., Nagai M., Frey J., and Bagdasarian M. Immunogenicity of Actinobacillus ApxIA toxin epitopes fused to the E. coli heat-labile enterotoxin B subunit. Vaccine 17 5 (1999) 441-447
20. Haesebrouck F., Chiers K., Van Overbeke I., and Ducatelle R. Actinobacillus pleuropneumoniae infections in pigs: the role of virulence factors in pathogenesis and protection. Vet Microbiol 58 2-4 (1997) 239-249
21. Seah J.N., Frey J., and Kwang J. The N-terminal domain of RTX toxin ApxI of Actinobacillus pleuropneumoniae elicits protective immunity in mice. Infect Immun 70 11 (2002) 6464-6467
22. Tumamao J.Q., Bowles R.E., van den Bosch H., Klaasen H.L., Fenwick B.W., Storie G.J., et al. Comparison of the efficacy of a subunit and a live streptomycin-dependent porcine pleuropneumonia vaccine. Aust Vet J 82 6 (2004) 370-374
23. Chiers K., van Overbeke I., De Laender P., Ducatelle R., Carel S., and Haesebrouck F. Effects of endobronchial challenge with Actinobacillus pleuropneumoniae serotype 9 of pigs vaccinated with inactivated vaccines containing the Apx toxins. Vet Q 20 2 (1998) 65-69
24. Willson P.J., Gerlach G.F., Klashinsky S., and Potter A.A. Cloning and characterization of the gene coding for NADPH-sulfite reductase hemoprotein from Actinobacillus pleuropneumoniae and use of the protein product as a vaccine. Can J Vet Res 65 4 (2001) 206-212
25. Rossi-Campos A., Anderson C., Gerlach G.F., Klashinsky S., Potter A.A., and Willson P.J. Immunization of pigs against Actinobacillus pleuropneumoniae with two recombinant protein preparations. Vaccine 10 8 (1992) 512-518
26. Osorio J.E., Tomlinson C.C., Frank R.S., Haanes E.J., Rushlow K., Haynes J.R., et al. Immunization of dogs and cats with a DNA vaccine against rabies virus. Vaccine 17 9-10 (1999) 1109-1116
27. Chen Y.L., Wang S.N., Yang W.J., Chen Y.J., Lin H.H., and Shiuan D. Expression and immunogenicity of Mycoplasma hyopneumoniae heat shock protein antigen P42 by DNA vaccination. Infect Immun 71 3 (2003) 1155-1160
28. Rogers W.O., Gowda K., and Hoffman S.L. Construction and immunogenicity of DNA vaccine plasmids encoding four Plasmodium vivax candidate vaccine antigens. Vaccine 17 23-24 (1999) 3136-3144
29. Saldarriaga O.A., Travi B.L., Park W., Perez L.E., and Melby P.C. Immunogenicity of a multicomponent DNA vaccine against visceral leishmaniasis in dogs. Vaccine 24 11 (2006) 1928-1940
30. Hung C.F., Calizo R., Tsai Y.C., He L., and Wu T.C. A DNA vaccine encoding a single-chain trimer of HLA-A2 linked to human mesothelin peptide generates anti-tumor effects against human mesothelin-expressing tumors. Vaccine 25 1 (2007) 127-135
31. Gurunathan S., Klinman D.M., and Seder R.A. DNA vaccines: immunology, application, and optimization. Annu Rev Immunol 18 (2000) 927-974
32. Liao C.W., Chiou H.Y., Yeh K.S., Chen J.R., and Weng C.N. Oral immunization using formalin-inactivated Actinobacillus pleuropneumoniae antigens entrapped in microspheres with aqueous dispersion polymers prepared using a co-spray drying process. Prev Vet Med 61 1 (2003) 1-15
33. Yang W.J., Lai J.F., Peng K.C., Chiang H.J., Weng C.N., and Shiuan D. Epitope mapping of Mycoplasma hyopneumoniae using phage displayed peptide libraries and the immune responses of the selected phagotopes. J Immunol Methods 304 1-2 (2005) 15-29
34. Jolie R.A., Mulks M.H., and Thacker B.J. Cross-protection experiments in pigs vaccinated with Actinobacillus pleuropneumoniae subtypes 1A and 1B. Vet Microbiol 45 4 (1995) 383-391
35. Haga Y., Ogino S., Ohashi S., Ajito T., Hashimoto K., and Sawada T. Protective efficacy of an affinity-purified hemolysin vaccine against experimental swine pleuropneumonia. J Vet Med Sci 59 2 (1997) 115-120
36. Salonius K., Simard N., Harland R., and Ulmer J.B. The road to licensure of a DNA vaccine. Curr Opin Investig Drugs 8 8 (2007) 635-641
37. Shin S.J., Shin S.W., Kang M.L., Lee D.Y., Yang M.S., Jang Y.S., et al. Enhancement of protective immune responses by oral vaccination with Saccharomyces cerevisiae expressing recombinant Actinobacillus pleuropneumoniae ApxIA or ApxIIA in mice. J Vet Sci 8 4 (2007) 383-392
38. Park J.H., Kim S.J., Oem J.K., Lee K.N., Kim Y.J., Kye S.J., et al. Enhanced immune response with foot and mouth disease virus VP1 and interleukin-1 fusion genes. J Vet Sci 7 3 (2006) 257-262
39. Beaudet R., McSween G., Boulay G., Rousseau P., Bisaillon J.G., Descoteaux J.P., et al. Protection of mice and swine against infection with Actinobacillus pleuropneumoniae by vaccination. Vet Microbiol 39 1-2 (1994) 71-81